Information Provided By: 
Fly News Breaks for August 21, 2017
PCRX
Aug 21, 2017 | 09:21 EDT
As previously reported, Janney Capital analyst Ken Trbovich upgraded Pacira to Neutral from Sell, saying he no longer sees significant downside after the stock's nearly 30% decline over the past month. However, he believes upside is dependent on growth for Exparel accelerating to at least the upper-end of the company's guidance of 12%-27% in the second half. He keeps a $36 fair value estimate on Pacira shares.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
